JP6305920B2 - 併用療法 - Google Patents

併用療法 Download PDF

Info

Publication number
JP6305920B2
JP6305920B2 JP2014517338A JP2014517338A JP6305920B2 JP 6305920 B2 JP6305920 B2 JP 6305920B2 JP 2014517338 A JP2014517338 A JP 2014517338A JP 2014517338 A JP2014517338 A JP 2014517338A JP 6305920 B2 JP6305920 B2 JP 6305920B2
Authority
JP
Japan
Prior art keywords
cancer
receptor
individual
cell
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014517338A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520759A5 (https=
JP2014520759A (ja
Inventor
ジュリアン・アレクサンダー・バーデン
アンガス・ギドリー−ベアード
Original Assignee
バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011902623A external-priority patent/AU2011902623A0/en
Application filed by バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド filed Critical バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド
Publication of JP2014520759A publication Critical patent/JP2014520759A/ja
Publication of JP2014520759A5 publication Critical patent/JP2014520759A5/ja
Application granted granted Critical
Publication of JP6305920B2 publication Critical patent/JP6305920B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014517338A 2011-07-01 2012-07-02 併用療法 Active JP6305920B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2011902623 2011-07-01
AU2011902623A AU2011902623A0 (en) 2011-07-01 Combination therapy
PCT/AU2012/000795 WO2013003895A1 (en) 2011-07-01 2012-07-02 Combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018039564A Division JP6490270B2 (ja) 2011-07-01 2018-03-06 併用療法

Publications (3)

Publication Number Publication Date
JP2014520759A JP2014520759A (ja) 2014-08-25
JP2014520759A5 JP2014520759A5 (https=) 2015-08-20
JP6305920B2 true JP6305920B2 (ja) 2018-04-04

Family

ID=47436374

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014517338A Active JP6305920B2 (ja) 2011-07-01 2012-07-02 併用療法
JP2018039564A Active JP6490270B2 (ja) 2011-07-01 2018-03-06 併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018039564A Active JP6490270B2 (ja) 2011-07-01 2018-03-06 併用療法

Country Status (11)

Country Link
US (3) US9566318B2 (https=)
EP (1) EP2726095B1 (https=)
JP (2) JP6305920B2 (https=)
CN (1) CN103702683B (https=)
AU (1) AU2012278921B2 (https=)
BR (1) BR112013033974A2 (https=)
CA (1) CA2840251C (https=)
ES (1) ES2689272T3 (https=)
MX (1) MX349321B (https=)
WO (1) WO2013003895A1 (https=)
ZA (1) ZA201400120B (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10010075B2 (en) 2010-12-29 2018-07-03 Ecolab Usa Inc. Water temperature as a means of controlling kinetics of onsite generated peracids
US10233149B2 (en) 2014-12-18 2019-03-19 Ecolab Usa Inc. Methods for forming peroxyformic acid and uses thereof
US10433547B2 (en) 2014-12-18 2019-10-08 Ecolab Usa Inc. Generation of peroxyformic acid through polyhydric alcohol formate
US10477862B2 (en) 2010-12-29 2019-11-19 Ecolab Usa Inc. In situ generation of peroxycarboxylic acids at alkaline pH, and methods of use thereof
US11040902B2 (en) 2014-12-18 2021-06-22 Ecolab Usa Inc. Use of percarboxylic acids for scale prevention in treatment systems
US11180385B2 (en) 2012-10-05 2021-11-23 Ecolab USA, Inc. Stable percarboxylic acid compositions and uses thereof
US12058999B2 (en) 2018-08-22 2024-08-13 Ecolab Usa Inc. Hydrogen peroxide and peracid stabilization with molecules based on a pyridine carboxylic acid

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
MX2019004410A (es) * 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CN114173811A (zh) * 2019-07-26 2022-03-11 生物权威(澳大利亚)有限责任公司 P2x7受体靶向治疗

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
AU2566595A (en) 1994-05-27 1995-12-21 Glaxo Group Limited P-2x receptors (purinoceptor family)
WO1997006256A2 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
JP2001521372A (ja) 1996-04-30 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ヒトＰ２ｘ４レセプタースプライス−変異体
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
EP1086223B1 (en) 1998-06-01 2009-07-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
NL1012452C2 (nl) 1999-06-28 2001-01-02 Univ Delft Tech Werkwijze voor de bereiding van eiwit-agglomeraten, eiwit-agglomeraten, een levensmiddel en een farmaceutisch preparaat die deze bevatten alsmede een inrichting voor het bereiden van eiwit-agglomeraten.
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
CN100497386C (zh) 2001-09-03 2009-06-10 因特里特有限公司 非功能性p2x7受体的抗体及其应用
EP1469072B1 (en) 2003-04-17 2007-08-29 Affectis Pharmaceuticals AG Means and methods for diagnosing and treating affective disorders
DE602005017743D1 (de) * 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US7858323B2 (en) * 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
GB0419295D0 (en) * 2004-08-31 2004-09-29 Genomica Sau Methods and compositions to prevent neuronal degeneration
CA2607541A1 (en) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008043146A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
JP2010505426A (ja) 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
ES2619681T3 (es) * 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
KR20170097234A (ko) * 2008-12-10 2017-08-25 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 유방암 재발 예방용 백신
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) * 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
US8828944B2 (en) * 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10010075B2 (en) 2010-12-29 2018-07-03 Ecolab Usa Inc. Water temperature as a means of controlling kinetics of onsite generated peracids
US10201156B2 (en) 2010-12-29 2019-02-12 Ecolab Usa Inc. Continuous on-line adjustable disinfectant/sanitizer/bleach generator
US11311011B2 (en) 2010-12-29 2022-04-26 Ecolab Usa Inc. Continuous on-line adjustable disinfectant/sanitizer/bleach generator
US10244751B2 (en) 2010-12-29 2019-04-02 Ecolab Usa Inc. Water temperature as a means of controlling kinetics of onsite generated peracids
US10477862B2 (en) 2010-12-29 2019-11-19 Ecolab Usa Inc. In situ generation of peroxycarboxylic acids at alkaline pH, and methods of use thereof
US11180385B2 (en) 2012-10-05 2021-11-23 Ecolab USA, Inc. Stable percarboxylic acid compositions and uses thereof
US10542751B2 (en) 2014-12-18 2020-01-28 Ecolab Usa Inc. Generation of peroxyformic acid through polyhydric alcohol formate
US10709131B2 (en) 2014-12-18 2020-07-14 Ecolab Usa Inc. Generation of peroxyformic acid through polyhydric alcohol formate
US10834924B2 (en) 2014-12-18 2020-11-17 Ecolab Usa Inc. Generation of peroxyformic acid through polyhydric alcohol formate
US10899707B2 (en) 2014-12-18 2021-01-26 Ecolab Usa Inc. Methods for forming peroxyformic acid and uses thereof
US11040902B2 (en) 2014-12-18 2021-06-22 Ecolab Usa Inc. Use of percarboxylic acids for scale prevention in treatment systems
US10433547B2 (en) 2014-12-18 2019-10-08 Ecolab Usa Inc. Generation of peroxyformic acid through polyhydric alcohol formate
US10233149B2 (en) 2014-12-18 2019-03-19 Ecolab Usa Inc. Methods for forming peroxyformic acid and uses thereof
US11684067B2 (en) 2014-12-18 2023-06-27 Ecolab Usa Inc. Generation of peroxyformic acid through polyhydric alcohol formate
US12058999B2 (en) 2018-08-22 2024-08-13 Ecolab Usa Inc. Hydrogen peroxide and peracid stabilization with molecules based on a pyridine carboxylic acid

Also Published As

Publication number Publication date
ES2689272T3 (es) 2018-11-13
BR112013033974A2 (pt) 2017-02-14
AU2012278921A1 (en) 2014-01-16
ZA201400120B (en) 2015-09-30
EP2726095A4 (en) 2015-01-07
CA2840251A1 (en) 2013-01-10
JP2018087249A (ja) 2018-06-07
US10543262B2 (en) 2020-01-28
US20190224290A1 (en) 2019-07-25
CN103702683A (zh) 2014-04-02
US20150004179A1 (en) 2015-01-01
US20170157229A1 (en) 2017-06-08
AU2012278921B2 (en) 2016-11-10
JP2014520759A (ja) 2014-08-25
CA2840251C (en) 2023-09-12
MX349321B (es) 2017-07-21
EP2726095B1 (en) 2018-06-06
MX2014000199A (es) 2014-06-11
CN103702683B (zh) 2017-07-04
US10245308B2 (en) 2019-04-02
JP6490270B2 (ja) 2019-03-27
EP2726095A1 (en) 2014-05-07
WO2013003895A1 (en) 2013-01-10
US9566318B2 (en) 2017-02-14

Similar Documents

Publication Publication Date Title
JP6490270B2 (ja) 併用療法
CN102762595B (zh) 针对非功能性低聚p2x7受体的抗体
JP2023509323A (ja) 抗ｃｃｒ８抗体及びその使用
ES2990971T3 (es) Nuevos anticuerpos anti-SIRPa y sus aplicaciones terapéuticas
AU2011301153B2 (en) Companion animal treatments
US20230416367A1 (en) Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
JP7853205B2 (ja) Ｐ２ｘ７受容体の標的療法
CN115956088A (zh) 包括抗-CD19抗体和阻断SIRPα-CD47先天免疫检查点的多肽的抗肿瘤组合疗法
EP3389693A1 (en) COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES
HK1195258A (en) Combination therapy
HK1195258B (en) Combination therapy
CN103298487B (zh) 陪伴动物治疗
JP2022184105A (ja) 抗ｃｄ２６抗体と免疫チェックポイント阻害剤との併用療法
HK1188401B (en) Companion animal treatments
HK1188401A (en) Companion animal treatments

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180307

R150 Certificate of patent or registration of utility model

Ref document number: 6305920

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250